103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study

Background: Blood vascular angiosarcoma is an uncommon and aggressive malignancy that has responded well to several combinations of immunotherapy.Conventional medicines like radiation and chemotherapy are not very successful, however immunotherapies such bempegaldesleukin + nivolumab, epacadostat + pembrolizumab, and Immune checkpoint inhibitors (ICIs) have shown positive outcomes in certain individuals.Ipilimumab + nivolumab and pembrolizumab, have also demonstrated promise in slowing the course of the illness and raising survival rates.Methods: This study was conducted based on PRISMA reporting guidelines.All included studies were derived from PubMed, Sciencedirect, NEJM, and Europe PMC databases using a set of keywords: Angiosarcoma, Pembrolizumab, and Immunotherapies.Studies were extracted and evaluated based on inclusion (Accessible full text, Randomized Controlled Trial, Clinical Trials, and last 5 years) and exclusion criterias (non-english text, animal studies, case report, systematic reviews, and meta analysis) The quality of included studies were further assessed using Newcastle-Ottawa Scale (NOS).Results: Seven studies consisting of RCTs and clinical trials were included, screening a total of 195 patients.Among the seven studies, bempegaldesleukin + nivolumab yields 0.60 (95% Cl; 0.08-4.40;P < 0.00001), epacadostat + pembrolizumab yields 0.03 (95% Cl; 0.00-0.29;P < 0.00001), ipilimumab + nivolumab yields 0.33 (95% Cl; 0.07-1.49;P < 0.00001), pembrolizumab alone yields 3.33 (95% Cl; 0.36-30.70;P < 0.00001), and Immune checkpoint inhibitors (ICIs) yields 0.13 (95% Cl; 0.02-0.71;P < 0.00001) Adverse effect wise is 17.00 (95% Cl; 0.74-391.68;P < 0.00001), 0.30 (95% Cl; 0.10-0.92;P < 0.00001), 3.00 (95% Cl; 0.67-13.40;P < 0.00001), 0.09 (95% Cl; 0.00-2.07;P < 0.00001), and 5.00 (95% Cl; 1.07-23.46;P < 0.00001), respectively.Conclusions: This research shows that monotherapy drugs, pembrolizumab alone, are better than other combinations and ICIs in terms of ORR and adverse effect.